COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 26, 2015, Pages 8070-8075

  Larsson, Karin ^a   Kock, Anna ^b   Idborg, Helena ^a   Henriksson, Marie Arsenian ^a   Martinsson, Tommy ^c   Johnsen, John I ^b   Korotkova, Marina ^a   Kogner, Per ^b   Jakobsson, Per Johan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cancer associated fibroblasts; MPGES 1; Neuroblastoma; PGE2; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD163 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SEPRASE; VIMENTIN; ISOMERASE; MESSENGER RNA; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME DELETION; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CHROMOSOME 11; DISEASE MODEL; ENZYMOLOGY; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; DINOPROSTONE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; MICE; NEUROBLASTOMA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; TUMOR MICROENVIRONMENT;

EID: 84937868651     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424355112     Document Type: Article

References (48)

1. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202-2211.
2. Cohn SL, et al.; INRG Task Force (2009) The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27(2):289-297.
3. Carén H, et al. (2010) High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 107(9):4323-4328.
4. Brodeur GM, Bagatell R (2014) Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol 11(12):704-713.
5. D'Angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1(7708):1046-1049.
6. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181-193.
7. Yoshimatsu K, et al. (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7(12):3971-3976.
8. van Rees BP, et al. (2003) Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 107(4):551-556.
9. Sasaki Y, et al. (2012) Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene 31(24):2943-2952.
10. Yoshimatsu K, et al. (2001) Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 7(9):2669-2674.
11. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC (2008) Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 68(19):7750-7759.
12. Hanaka H, et al. (2009) Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci USA 106(44):18757-18762.
13. Pai R, et al. (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8(3):289-293.
14. Sheng H, Shao J, Washington MK, DuBois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276(21):18075-18081.
15. Buchanan FG, Wang D, Bargiacchi F, DuBois RN (2003) Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278(37):35451-35457.
16. Pai R, et al. (2001) PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 286(5):923-928.
17. Trompezinski S, Pernet I, Schmitt D, Viac J (2001) UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res 50(8):422-427.
18. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58(2):362-366.
19. Kurtova AV, et al. (2015) Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517(7533):209-213.
20. Obermajer N, et al. (2012) PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 41(6-7):635-657.
21. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188(1):21-28.
22. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
23. Asgharzadeh S, et al. (2012) Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 30(28):3525-3532.
24. Kharaishvili G, et al. (2014) The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int 14:41-48.
25. Zeine R, et al. (2009) Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Mod Pathol 22(7):950-958.
26. Carlson LM, et al. (2013) Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis 34(5):1081-1088.
27. Johnsen JI, et al. (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64(20):7210-7215.
28. Ponthan F, et al. (2007) Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13(3):1036-1044.
29. Rasmuson A, et al. (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS ONE 7(1):e29331.
30. Yu AL, et al.; Children's Oncology Group (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324-1334.
31. Westman M, et al. (2004) Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 50(6):1774-1780.
32. Kryh H, et al. (2011) Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics 12:443-453.
33. Ladenstein R, et al. (2010) Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J Clin Oncol 28(21):3516-3524.
34. Salvado MD, Alfranca A, Escolano A, Haeggström JZ, Redondo JM (2009) COX-2 limits prostanoid production in activated HUVECs and is a source of PGH2 for transcellular metabolism to PGE2 by tumor cells. Arterioscler Thromb Vasc Biol 29(7):1131-1137.
35. Pistoia V, et al. (2013) Immunosuppressive microenvironment in neuroblastoma. Front Oncol 3:167-174.
36. Santilli G, et al. (2013) Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clin Cancer Res 19(5):1116-1125.
37. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890.
38. Donnini S, et al. (2012) EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity. Oncogene 31(29):3457-3466.
39. Alcolea S, et al. (2012) Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2. J Lipid Res 53(4):630-642.
40. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell 17(2):135-147.
41. Cortez E, Roswall P, Pietras K (2014) Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25:3-9.
42. Paulsson J, Micke P (2014) Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol 25:61-68.
43. Kakarla S, Song XT, Gottschalk S (2012) Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4(11):1129-1138.
44. Li HJ, Reinhardt F, Herschman HR, Weinberg RA (2012) Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2(9):840-855.
45. Baryawno N, et al. (2008) Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro-oncol 10(5):661-674.
46. Idborg H, et al. (2013) Effects of mPGES-1 deletion on eicosanoid and fatty acid profiles in mice. Prostaglandins Other Lipid Mediat 107:18-25.
47. Melin E, Lindroos E, Lundberg IE, Borg K, Korotkova M (2014) Elevated expression of prostaglandin E2 synthetic pathway in skeletal muscle of prior polio patients. J Rehabil Med 46(1):67-72.
48. Pearson AD, et al.; European Neuroblastoma Study Group; Children's Cancerand Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group) (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9(3):247-256.